Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

Author:

Davies Nicholas G.1ORCID,Abbott Sam1ORCID,Barnard Rosanna C.1ORCID,Jarvis Christopher I.1ORCID,Kucharski Adam J.1,Munday James D.1ORCID,Pearson Carl A. B.1ORCID,Russell Timothy W.1ORCID,Tully Damien C.1ORCID,Washburne Alex D.2ORCID,Wenseleers Tom3ORCID,Gimma Amy1,Waites William1ORCID,Wong Kerry L. M.1ORCID,van Zandvoort Kevin1ORCID,Silverman Justin D.4ORCID,Diaz-Ordaz Karla5ORCID,Keogh Ruth5ORCID,Eggo Rosalind M.1ORCID,Funk Sebastian1ORCID,Jit Mark1ORCID,Atkins Katherine E.16ORCID,Edmunds W. John1ORCID, ,

Affiliation:

1. Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, UK.

2. Selva Analytics LLC, Bozeman, MT, USA.

3. Lab of Socioecology and Social Evolution, KU Leuven, Leuven, Belgium.

4. College of Information Science and Technology, Pennsylvania State University, University Park, PA, USA.

5. Centre for Statistical Methodology and Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK.

6. Centre for Global Health, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.

Abstract

UK variant transmission Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has the capacity to generate variants with major genomic changes. The UK variant B.1.1.7 (also known as VOC 202012/01) has many mutations that alter virus attachment and entry into human cells. Using a variety of statistical and dynamic modeling approaches, Davies et al. characterized the spread of the B.1.1.7 variant in the United Kingdom. The authors found that the variant is 43 to 90% more transmissible than the predecessor lineage but saw no clear evidence for a change in disease severity, although enhanced transmission will lead to higher incidence and more hospital admissions. Large resurgences of the virus are likely to occur after the easing of control measures, and it may be necessary to greatly accelerate vaccine roll-out to control the epidemic. Science , this issue p. eabg3055

Funder

University of Kentucky

Universität Bern

Universitätsspital Basel

National Institute for Health Research

European Commission

CANDU Owners Group

Hôpitaux Universitaires de Genève

Eidgenössische Technische Hochschule Zürich

Université de Sfax

UKRI Research England

National Institute for Health Research Health Protection Research Unit in Immunisation

United Kingdom Medical Research Council

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference75 articles.

1. Public Health England “Investigation of novel SARS-COV-2 variant: Variant of Concern 202012/01” (2020); www.gov.uk/government/publications/investigation-of-novel-sars-cov-2-variant-variant-of-concern-20201201.

2. Á. O’Toole “Tracking the international spread of SARS-CoV-2 lineages B.1.1.7 and B.1.351/501Y-V2” (2021); https://virological.org/t/tracking-the-international-spread-of-sars-cov-2-lineages-b-1-1-7-and-b-1-351-501y-v2/592.

3. Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy

4. Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding

5. A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells

Cited by 2226 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3